Financial Performance - Teledyne Technologies reported quarterly earnings of $5.2 per share, exceeding the Zacks Consensus Estimate of $5.02 per share, and up from $4.58 per share a year ago, representing an earnings surprise of +3.59% [1] - The company posted revenues of $1.51 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.84%, compared to revenues of $1.37 billion in the same quarter last year [2] - Over the last four quarters, Teledyne has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance - Teledyne shares have increased approximately 19.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.3% [3] - The current Zacks Rank for Teledyne is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $5.52 on revenues of $1.54 billion, and for the current fiscal year, it is $21.45 on revenues of $6.05 billion [7] - The outlook for the Aerospace - Defense Equipment industry, where Teledyne operates, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable environment for performance [8]

分组1 - TE Connectivity (TEL) reported quarterly earnings of $2.27 per share, exceeding the Zacks Consensus Estimate of $2.08 per share, and showing an increase from $1.91 per share a year ago, resulting in an earnings surprise of +9.13% [1] - The company achieved revenues of $4.53 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.20%, and up from $3.98 billion year-over-year [2] - TE Connectivity has outperformed the S&P 500, with shares increasing by about 26.2% since the beginning of the year compared to the S&P 500's gain of 7.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $2.13 on revenues of $4.38 billion, and for the current fiscal year, it is $8.27 on revenues of $16.67 billion [7] - The Zacks Industry Rank for Electronics - Miscellaneous Components is in the top 28% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

What's Next for Koninklijke KPN? While Koninklijke KPN has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlatio ...

分组1 - Baker Hughes reported quarterly earnings of $0.63 per share, exceeding the Zacks Consensus Estimate of $0.55 per share, and showing an earnings surprise of +14.55% [1] - The company posted revenues of $6.91 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.17%, although this represents a decline from year-ago revenues of $7.14 billion [2] - Over the last four quarters, Baker Hughes has consistently surpassed consensus EPS estimates, achieving this four times [2] 分组2 - The stock has underperformed the market, losing about 2.9% since the beginning of the year compared to the S&P 500's gain of 7.2% [3] - The current consensus EPS estimate for the upcoming quarter is $0.61 on revenues of $6.81 billion, and for the current fiscal year, it is $2.37 on revenues of $26.95 billion [7] - The Zacks Industry Rank indicates that the Oil and Gas - Field Services sector is currently in the bottom 5% of over 250 Zacks industries, which may negatively impact stock performance [8]

Group 1: Earnings Performance - USANA Health Sciences reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.54 per share, and up from $0.54 per share a year ago, representing an earnings surprise of +37.04% [1] - The company posted revenues of $235.85 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.73%, compared to year-ago revenues of $212.87 million [2] - Over the last four quarters, USANA has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - USANA Health shares have declined approximately 15.6% since the beginning of the year, while the S&P 500 has gained 7.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.65 on revenues of $225.82 million, and for the current fiscal year, it is $2.61 on revenues of $946.98 million [7] Group 3: Industry Context - The Medical - Drugs industry, to which USANA belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact USANA's stock performance [5] - Another company in the same industry, Aquestive Therapeutics, is expected to report a quarterly loss of $0.18 per share, reflecting a significant year-over-year decline [9]

Core Viewpoint - Southern First (SFST) reported quarterly earnings of $0.81 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, and showing significant growth from $0.37 per share a year ago, indicating strong financial performance [1][2] Financial Performance - The company achieved revenues of $28.63 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.81%, compared to $23.05 million in the same quarter last year [2] - Southern First has consistently outperformed consensus EPS estimates over the last four quarters, achieving earnings surprises of +24.62% in the latest quarter and +6.56% in the previous quarter [1][2] Stock Performance and Outlook - Southern First shares have increased by approximately 0.9% since the beginning of the year, underperforming compared to the S&P 500's gain of 7.2% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.73 on revenues of $27.89 million, and for the current fiscal year, it is $2.79 on revenues of $108.88 million [7] - The trend of earnings estimate revisions is mixed ahead of the earnings release, which may influence future stock performance [6] Industry Context - The Banks - Southeast industry, to which Southern First belongs, is currently ranked in the top 16% of over 250 Zacks industries, suggesting a favorable environment for performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

分组1 - Avery Dennison reported quarterly earnings of $2.42 per share, exceeding the Zacks Consensus Estimate of $2.38 per share, with an earnings surprise of +1.68% [1] - The company posted revenues of $2.22 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.5%, and compared to year-ago revenues of $2.24 billion [2] - The stock has underperformed the market, losing about 4.3% since the beginning of the year, while the S&P 500 gained 7.2% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $2.37 on revenues of $2.21 billion, and for the current fiscal year, it is $9.56 on revenues of $8.83 billion [7] - The Containers - Paper and Packaging industry is currently in the top 40% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Danaher (DHR) reported quarterly earnings of $1.8 per share, exceeding the Zacks Consensus Estimate of $1.64 per share, and showing a year-over-year decrease from $1.72 per share [1] Financial Performance - The company achieved revenues of $5.94 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.71% and increasing from $5.74 billion year-over-year [2] - Over the last four quarters, Danaher has exceeded consensus EPS estimates three times and topped revenue estimates four times [2] Stock Performance - Danaher shares have declined approximately 18.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.2% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.80 on revenues of $6.02 billion, and for the current fiscal year, it is $7.70 on revenues of $24.52 billion [7] - The trend of estimate revisions for Danaher was unfavorable prior to the earnings release, which may impact future stock performance [6] Industry Context - The Medical Services industry, to which Danaher belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - Medpace reported quarterly earnings of $3.1 per share, exceeding the Zacks Consensus Estimate of $3 per share, and up from $2.75 per share a year ago, representing an earnings surprise of +3.33% [1] - The company posted revenues of $603.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.48%, compared to year-ago revenues of $528.1 million [2] - Over the last four quarters, Medpace has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Medpace shares have declined approximately 6.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $2.95 for the coming quarter and $12.68 for the current fiscal year [4][7] - The estimate revisions trend for Medpace was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Medpace belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Medpace's stock may also be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]

Group 1 - Crown Holdings reported quarterly earnings of $2.15 per share, exceeding the Zacks Consensus Estimate of $1.86 per share, and up from $1.81 per share a year ago, representing an earnings surprise of +15.59% [1] - The company posted revenues of $3.15 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.39%, and an increase from $3.04 billion year-over-year [2] - Crown has outperformed the S&P 500 with a stock price increase of about 28.5% since the beginning of the year, compared to the S&P 500's gain of 7.1% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.98 on revenues of $3.16 billion, and for the current fiscal year, it is $7.11 on revenues of $12.16 billion [7] - The Containers - Metal and Glass industry, to which Crown belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] Group 3 - The estimate revisions trend for Crown was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]